JAMA Surgery· 2016Q1· Guideline
The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism
- 1,293citations
- Q1SCImago
- 2016year
Short summary
New guidelines recommend parathyroidectomy for most primary hyperparathyroidism (pHPT) patients, citing it as more cost-effective than observation or medication, and recommend specific imaging and intraoperative monitoring for optimal surgical outcomes.
AI-generated from the title and abstract; the full text is not read.
Key points
- Parathyroidectomy is recommended for all symptomatic and most asymptomatic primary hyperparathyroidism (pHPT) patients.
- Parathyroidectomy is more cost-effective than observation or pharmacologic therapy for pHPT.
- Preoperative imaging (ultrasonography or other high-resolution) is recommended for operative planning.
- Intraoperative parathyroid hormone monitoring is recommended for minimally invasive parathyroidectomy, but not for suspected multigland disease.
AI-generated from the title and abstract; the full text is not read.
Abstract
Importance: Primary hyperparathyroidism (pHPT) is a common clinical problem for which the only definitive management is surgery. Surgical management has evolved considerably during the last several decades. Objective: To develop evidence-based guidelines to enhance the appropriate, safe, and effective practice of parathyroidectomy. Evidence Review: A multidisciplinary panel used PubMed to review the medical literature from January 1, 1985, to July 1, 2015. Levels of evidence were determined using the American College of Physicians grading system, and recommendations were discussed until consensus. Findings: Initial evaluation should include 25-hydroxyvitamin D measurement, 24-hour urine calcium measurement, dual-energy x-ray absorptiometry, and supplementation for vitamin D deficiency. Parathyroidectomy is indicated for all symptomatic patients, should be considered for most asymptomatic patients, and is more cost-effective than observation or pharmacologic therapy. Cervical ultrasonography or other high-resolution imaging is recommended for operative planning. Patients with nonlocalizing imaging remain surgical candidates. Preoperative parathyroid biopsy should be avoided. Surgeons who perform a high volume of operations have better outcomes. The possibility of multigland disease should be routinely considered. Both focused, image-guided surgery (minimally invasive parathyroidectomy) and bilateral exploration are appropriate operations that achieve high cure rates. For minimally invasive parathyroidectomy, intraoperative parathyroid hormone monitoring via a reliable protocol is recommended. Minimally invasive parathyroidectomy is not routinely recommended for known or suspected multigland disease. Ex vivo aspiration of resected parathyroid tissue may be used to confirm parathyroid tissue intraoperatively. Clinically relevant thyroid disease should be assessed preoperatively and managed during parathyroidectomy. Devascularized normal parathyroid tissue should be autotransplanted. Patients should be observed postoperatively for hematoma, evaluated for hypocalcemia and symptoms of hypocalcemia, and followed up to assess for cure defined as eucalcemia at more than 6 months. Calcium supplementation may be indicated postoperatively. Familial pHPT, reoperative parathyroidectomy, and parathyroid carcinoma are challenging entities that require special consideration and expertise. Conclusions and Relevance: Evidence-based recommendations were created to assist clinicians in the optimal treatment of patients with pHPT.
The authors' abstract, as published at the source. JAMA Surgery, 2016 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Nephrology
NephrologyMedicine